Gene:
NR1I3
nuclear receptor subfamily 1, group I, member 3

PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no clinical annotations for this gene. To report clinical variants, click here.

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

Overview

Alternate Names:  OTTHUMP00000032245; OTTHUMP00000032246; OTTHUMP00000217486; OTTHUMP00000217487; OTTHUMP00000217488; OTTHUMP00000217492; OTTHUMP00000217493; OTTHUMP00000217499; OTTHUMP00000217501; OTTHUMP00000217508; OTTHUMP00000217509; OTTHUMP00000217510; constitutive activator of retinoid response; constitutive active receptor; constitutive active response; constitutive androstane receptor; constitutive androstane receptor SV1; constitutive androstane receptor SV10; constitutive androstane receptor SV12; constitutive androstane receptor SV14; constitutive androstane receptor SV6; constitutive androstane receptor SV7; constitutive androstane receptor SV9; constitutive androstane receptor-beta; nuclear receptor subfamily 1 group I member 3; orphan nuclear hormone receptor; orphan nuclear receptor MB67
Alternate Symbols:  CAR; CAR-BETA; CAR-SV1; CAR-SV10; CAR-SV11; CAR-SV12; CAR-SV13; CAR-SV14; CAR-SV15; CAR-SV17; CAR-SV18; CAR-SV19; CAR-SV20; CAR-SV21; CAR-SV4; CAR-SV6; CAR-SV7; CAR-SV8; CAR-SV9; CAR1; MB67; MGC150433; MGC97144; MGC97209
PharmGKB Accession Id: PA391

Details

Cytogenetic Location: chr1 : q23.3 - q23.3
GP mRNA Boundary†: chr1 : 161199456 - 161208000
GP Gene Boundary†: chr1 : 161196456 - 161218000
Strand: minus
Product Name: No data available
† The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Carbamazepine Pathway, Pharmacokinetics
    Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.

External Pathways

Links to non-PharmGKB pathways.

  1. mechanism of acetaminophen activity and toxicity - (BioCarta via Pathway Interaction Database)
  2. Regulation of glucocorticoid receptor - (Pathway Interaction Database NCI-Nature Curated)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
CYP2B6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
CYP3A4

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
carbamazepine
No related diseases are available

Publications related to NR1I3: 17

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
PharmGKB summary: carbamazepine pathway. Pharmacogenetics and genomics. 2011. Thorn Caroline F, et al. [Article:21738081@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clinical pharmacology and therapeutics. 2010. Mathias A A, et al. [Article:20043009@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. [Article:20648701@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. The Journal of pharmacology and experimental therapeutics. 2010. Chaudhry Amarjit S, et al. [Article:19855097@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms in the TATA box and upstream phenobarbital-responsive enhancer module of the UGT1A1 promoter have combined effects on UDP-glucuronosyltransferase 1A1 transcription mediated by constitutive androstane receptor, pregnane X receptor, or glucocorticoid receptor in human liver. Drug metabolism and disposition: the biological fate of chemicals. 2009. Li Ye, et al. [Article:19541828@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug metabolism and disposition: the biological fate of chemicals. 2009. Tolson Antonia H, et al. [Article:19520773@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug metabolism and disposition: the biological fate of chemicals. 2008. Hariparsad Niresh, et al. [Article:18332078@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. The Journal of pharmacology and experimental therapeutics. 2007. Faucette Stephanie R, et al. [Article:17041008@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clinical pharmacology and therapeutics. 2006. Oscarson Mikael, et al. [Article:17112801@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin. European journal of clinical investigation. 2006. Simonsson U S H, et al. [Article:16919048@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Molecular pharmacology. 2006. Duret Cedric, et al. [Article:16608920@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacogenetics of HIV therapy. The pharmacogenomics journal. 2006. Rodríguez-Nóvoa S, et al. [Article:16462814@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional constraints on the constitutive androstane receptor inferred from human sequence variation and cross-species comparisons. Human genomics. 2005. Thompson Emma E, et al. [Article:16197734@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Molecular pharmacology. 2005. Burk Oliver, et al. [Article:15761118@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. The Journal of pharmacology and experimental therapeutics. 2004. Lamba Jatinder K, et al. [Article:15194709@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of the nuclear receptor CAR as a coordinate regulator of hepatic gene expression in defense against chemical toxicity. Archives of biochemistry and biophysics. 2003. Yamamoto Yukio, et al. [Article:12464260@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. The Journal of biological chemistry. 2002. Drocourt Lionel, et al. [Article:11991950@PubMed]
PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.